Biotech | February 28, 2022
Myonex acquires clinical trial and drug wholesale business of Hubertus in Berlin
Clinical trial supply company strengthens its presence in the European Union
Clinical trial supply company strengthens its presence in the European Union
Confirmed positive phase 3 topline results in addition to Enavogliflozin monotherapy and Metformin combination therapy
The bulk drug plants that have already been commissioned include CDA, para amino phenol, atorvastatin, sulfadiazine, oxcarbazepine, levofloxacin, carbidopa and levodopa
He will be responsible for developing the company's pipeline of partnered and in-house discovery programs,
The researchers are of the view that the new drug designing strategy demonstrated by them could also be adopted to treat retroviral infections.
AMX0035 is an investigational therapy for the treatment of amyotrophic lateral sclerosis (ALS).
The Prescription Drug User Fee Action (PDUFA) date for adagrasib is December 14, 2022
The newly enhanced drug development platform will help empower innovators with the fastest development timelines
The supplemental adolescent approval enhances Solosec’s strong position as the first and only single-dose oral prescription antimicrobial agent approved for the treatment of both trichomoniasis and BV
AstraZeneca will hold the registration and manufacture Pulmicort Respules, while Glenmark will commercialize the product in Columbia
Subscribe To Our Newsletter & Stay Updated
